References Gallagher TJ, Razura DE, Li A, Kim I, Vukkadala N, Barbu AM
The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone
Lim C-E, Pasternak B, Eliasson B, Danaei G, Ueda P (2022) Use of sodiumglucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes
[60] evaluated for potential differences in oxytocin receptor expression and distribution in the brain as a potential explanation for differences between juvenile versus adult rat behavior governing social interactions
At Regency Medical Spa, our team is committed to helping you feel confident and prepared for every step of your weight loss journey